Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both

Circulation Journal

Volumn 74, Issue 6, 2010, Pages 1158-1164

  Miyazaki, Sakiko ^a   Kasai, Takatoshi ^b   Miyauchi, Katsumi ^b   Miyazaki, Tadashi ^a   Akimoto, Yoshinori ^b   Takagi, Atsutoshi ^b   Aihara, Kouichiro ^b   Kawamura, Masaki ^a   Suwa, Satoru ^a   Kojima, Satoshi ^a   Sumiyoshi, Masataka ^a   Daida, Hiroyuki ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Ejection fraction; Left ventricular end diastolic volume index; Left ventricular end systolic volume index; Matrix metalloproteinase 9; Renin angiotensin system

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GELATINASE B; TRANDOLAPRIL; VALSARTAN;

ABSENCE OF SIDE EFFECTS; ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; TETRAZOLES; TREATMENT OUTCOME; VALINE; VENTRICULAR REMODELING;

EID: 77953533506     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0412     Document Type: Article

References (21)

1. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
2. Pfeffer MA, Braunwald E. Ventricular remodeling after acute myocardial infarction: Experimental observations and clinical implications. Circulation 1990; 81: 1161-1172.
3. Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S, et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995; 25: 219-226.
4. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukuhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99: 3063-3070.
5. Ducharme A, Franz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
6. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5: 1135-1142.
7. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: Its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149.
8. Sawicki G, Menon V, Jugdutt BI. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail 2004; 10: 442-449.
9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
11. Kober L, Torp-Pedersen C, Calsen JE, Bagger H, Eliasen P, Lyngborg K, et al for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 1995; 333: 1670-1676.
12. Sutton SJM, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, et al. Quantitative two-dimensional echocardio-graphic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: The protective effects of captopril. Circulation 1994; 89: 68-75.
13. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
14. Yasuda S, Shimokawa H. Acute myocardial infarction. Circ J 2009; 73: 2000-2008.
15. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10: 328-333.
16. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling. Circulation 2006; 114: 1020-1027.
17. Orn S, Manhenke C, Squire IB, Ng LL, Anand I, Dickstein K. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: Relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Cardiac Fail 2007; 13: 843-849.
18. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR. Cardiac remodeling in end stage heart failure: Upregulation of matrix metalloproteinase (MMP) irrespective of underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002; 88: 525-530.
19. Tyagi SC, Hayden MR, Hall JE. Role of angiotensin in angiogenesis and cardiac fibrosis in heart failure. Prog Exp Cardiol 1998; 2: 537-549.
20. Suzuki H, Geshi E, Nanjyo S, Nakano H, Yamazaki J, Sato N, et al. Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study. Circ J 2009; 73: 918-924.
21. Scaglione R, Argano C, Di Chiara T, Parrinello G, Colomba D, Avellone G, et al. Effect of dual blockade of rennin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients. J Hum Hypertens 2007; 21: 307-315.